The Manufacturers Life Insurance Company Takes Position in Edwards Lifesciences Corporation $EW

The Manufacturers Life Insurance Company purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,453,357 shares of the medical research company’s stock, valued at approximately $131,472,000. The Manufacturers Life Insurance Company owned approximately 0.25% of Edwards Lifesciences at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Edwards Lifesciences in the second quarter valued at about $5,318,092,000. Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter worth about $803,686,000. Conway Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the second quarter worth about $954,000. Varma Mutual Pension Insurance Co acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $11,168,000. Finally, TD Asset Management Inc grew its holdings in shares of Edwards Lifesciences by 6.4% during the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after purchasing an additional 47,051 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Up 0.5%

EW opened at $90.92 on Wednesday. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a fifty day moving average of $89.35 and a 200-day moving average of $84.82. The stock has a market cap of $52.35 billion, a PE ratio of 52.25, a price-to-earnings-growth ratio of 2.37 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 2,425 shares of company stock worth $219,199. 0.31% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

EW has been the subject of several research reports. Evercore reissued an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Piper Sandler reissued an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, Mizuho upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.